[go: up one dir, main page]

CL2019000821A1 - Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) - Google Patents

Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Info

Publication number
CL2019000821A1
CL2019000821A1 CL2019000821A CL2019000821A CL2019000821A1 CL 2019000821 A1 CL2019000821 A1 CL 2019000821A1 CL 2019000821 A CL2019000821 A CL 2019000821A CL 2019000821 A CL2019000821 A CL 2019000821A CL 2019000821 A1 CL2019000821 A1 CL 2019000821A1
Authority
CL
Chile
Prior art keywords
methods
compositions
divisional application
arginase activity
inhibit arginase
Prior art date
Application number
CL2019000821A
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CL2019000821A1 publication Critical patent/CL2019000821A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UNA NUEVA CLASE DE COMPUESTOS QUE EXHIBEN ACTIVIDAD INHIBIDORA DE LA ACTIVIDAD HACIA LA ARGINASA, Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA INVENCIÓN. TAMBIÉN SE PROPORCIONAN EN EL PRESENTE DOCUMENTO LOS MÉTODOS PARA TRATAR EL CÁNCER CON LOS INHIBIDORES DE ARGINASA DE LA INVENCIÓN.
CL2019000821A 2015-10-30 2019-03-28 Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) CL2019000821A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
CL2019000821A1 true CL2019000821A1 (es) 2019-08-09

Family

ID=58631120

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2018001134A CL2018001134A1 (es) 2015-10-30 2018-04-27 Composiciones y métodos para inhibir la actividad arginasa
CL2019000821A CL2019000821A1 (es) 2015-10-30 2019-03-28 Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019000819A CL2019000819A1 (es) 2015-10-30 2019-03-28 Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019000820A CL2019000820A1 (es) 2015-10-30 2019-03-28 Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018001134A CL2018001134A1 (es) 2015-10-30 2018-04-27 Composiciones y métodos para inhibir la actividad arginasa

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2019000819A CL2019000819A1 (es) 2015-10-30 2019-03-28 Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019000820A CL2019000820A1 (es) 2015-10-30 2019-03-28 Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Country Status (36)

Country Link
US (4) US10065974B2 (es)
EP (3) EP3693375B1 (es)
JP (3) JP6833844B2 (es)
KR (2) KR102434308B1 (es)
CN (4) CN113150015A (es)
AU (3) AU2016343656B2 (es)
BR (3) BR122020022280B1 (es)
CA (1) CA3003271A1 (es)
CL (4) CL2018001134A1 (es)
CO (1) CO2018004750A2 (es)
CR (3) CR20180282A (es)
CY (1) CY1123557T1 (es)
DK (2) DK4011887T3 (es)
EA (1) EA038276B1 (es)
EC (1) ECSP18040250A (es)
ES (3) ES2991555T3 (es)
HR (1) HRP20201046T1 (es)
HU (1) HUE054972T2 (es)
IL (3) IL258731B (es)
LT (1) LT3368541T (es)
MA (2) MA43131B1 (es)
MD (1) MD3368541T2 (es)
MX (1) MX2018005294A (es)
MY (1) MY201783A (es)
NZ (1) NZ742742A (es)
PH (2) PH12018500899B1 (es)
PL (1) PL3368541T3 (es)
PT (1) PT3368541T (es)
RS (1) RS60695B1 (es)
SG (4) SG10201911402YA (es)
SI (1) SI3368541T1 (es)
SM (1) SMT202000469T1 (es)
TW (3) TWI734630B (es)
UA (1) UA125289C2 (es)
WO (1) WO2017075363A1 (es)
ZA (4) ZA201803556B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876955B (zh) 2010-04-22 2018-11-23 马尔斯公司 精氨酸酶抑制剂及其治疗应用
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
EA038276B1 (ru) 2015-10-30 2021-08-04 Калитера Байосайенсиз, Инк. (3r,4s)-3-амино-1-((s)-2-аминопропаноил)-4-(3-боронопропил)пирролидин-3-карбоновая кислота, композиции на ее основе и ее применение для лечения рака
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2017356942A1 (en) 2016-11-08 2019-05-23 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
SG10201911243WA (en) 2016-12-22 2020-02-27 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
MA48626A (fr) 2017-05-12 2020-03-18 Calithera Biosciences Inc Procédé de préparation de (3r,4s)-3-acétamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
SG11202008113RA (en) 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
US10851099B2 (en) 2018-03-29 2020-12-01 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
EP3810615B1 (en) 2018-06-20 2026-01-28 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
TWI828800B (zh) 2018-11-16 2024-01-11 美商阿克思生物科學有限公司 Arg1及/或arg2之抑制劑
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3897622B1 (en) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
US20220251116A1 (en) * 2019-02-06 2022-08-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
PH12021552036A1 (en) * 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
CN114127081B (zh) * 2019-07-23 2024-09-13 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
US12286403B2 (en) 2019-11-12 2025-04-29 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
MX2023000056A (es) 2020-07-02 2023-04-12 Incyte Corp Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
US20220041630A1 (en) * 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
CA3254582A1 (en) 2022-03-17 2023-09-21 Incyte Corporation TRICYCLIC UREA COMPOUNDS AS JAK2 INHIBITORS V617F
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
TW202440086A (zh) 2023-03-13 2024-10-16 美商英塞特公司 作為激酶抑制劑之雙環脲

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
WO1999019295A1 (en) 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
WO2009008415A1 (ja) 2007-07-12 2009-01-15 Sanyo Denki Co., Ltd. 二重反転式軸流送風機
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
ES2729474T3 (es) 2009-01-26 2019-11-04 Univ Pennsylvania Inhibidores de la arginasa y métodos de uso
CN104876955B (zh) 2010-04-22 2018-11-23 马尔斯公司 精氨酸酶抑制剂及其治疗应用
PL2632927T3 (pl) * 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
WO2012091757A1 (en) 2010-12-31 2012-07-05 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US9957271B2 (en) 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
AU2013337663A1 (en) * 2012-11-02 2015-06-11 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
CN105848680A (zh) * 2013-10-25 2016-08-10 药品循环有限责任公司 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
WO2016153078A1 (en) * 2015-03-20 2016-09-29 Opiyo Sammy Oyoo Use of suramin and arginase inhibitors in malignant neoplasia
MA42269A (fr) * 2015-06-23 2018-05-02 Calithera Biosciences Inc Compositions et procédés d'inhibition de l'activité de l'arginase
EA038276B1 (ru) 2015-10-30 2021-08-04 Калитера Байосайенсиз, Инк. (3r,4s)-3-амино-1-((s)-2-аминопропаноил)-4-(3-боронопропил)пирролидин-3-карбоновая кислота, композиции на ее основе и ее применение для лечения рака
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
CL2018001134A1 (es) 2018-10-26
DK4011887T3 (da) 2024-10-28
IL288225A (en) 2022-01-01
TW201726692A (zh) 2017-08-01
DK3368541T3 (da) 2020-06-29
MA50636A (fr) 2021-04-14
CL2019000820A1 (es) 2019-08-09
EP3693375B1 (en) 2022-02-16
PH12018500899A1 (en) 2018-10-29
ES2808988T3 (es) 2021-03-02
US20200223872A1 (en) 2020-07-16
AU2016343656B2 (en) 2020-09-17
CN113150015A (zh) 2021-07-23
MD3368541T2 (ro) 2020-09-30
CO2018004750A2 (es) 2018-10-31
CY1123557T1 (el) 2022-03-24
TWI734630B (zh) 2021-07-21
CN113201002A (zh) 2021-08-03
SI3368541T1 (sl) 2020-10-30
IL281503A (en) 2021-04-29
JP6833844B2 (ja) 2021-02-24
BR112018008746A2 (pt) 2018-10-30
HK1252560A1 (en) 2019-05-31
AU2016343656A1 (en) 2018-06-07
CN108271371B (zh) 2021-02-09
PL3368541T3 (pl) 2020-11-02
BR122020022275B1 (pt) 2022-05-03
TW202110858A (zh) 2021-03-16
MY201783A (en) 2024-03-18
CN108271371A (zh) 2018-07-10
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
EA038276B1 (ru) 2021-08-04
AU2020286278A1 (en) 2021-01-14
EP4011887A1 (en) 2022-06-15
KR20220118559A (ko) 2022-08-25
US20210061822A1 (en) 2021-03-04
EP3368541A4 (en) 2019-07-17
EP3368541A1 (en) 2018-09-05
TW202146028A (zh) 2021-12-16
CR20180282A (es) 2018-11-30
KR102434308B1 (ko) 2022-08-19
SMT202000469T1 (it) 2020-11-10
AU2022203703A1 (en) 2022-06-16
ZA201907093B (en) 2021-03-31
ES2910928T3 (es) 2022-05-17
LT3368541T (lt) 2020-09-25
ZA201907092B (en) 2021-04-28
US20170121352A1 (en) 2017-05-04
CR20210389A (es) 2021-09-16
ES2991555T3 (es) 2024-12-04
IL258731B (en) 2021-04-29
PT3368541T (pt) 2020-07-06
CR20210390A (es) 2021-10-19
BR112018008746A8 (pt) 2019-02-26
KR20180084063A (ko) 2018-07-24
MX2018005294A (es) 2018-09-21
UA125289C2 (uk) 2022-02-16
US10844080B2 (en) 2020-11-24
ZA201803556B (en) 2021-02-24
JP7032583B2 (ja) 2022-03-08
CL2019000819A1 (es) 2019-08-09
ECSP18040250A (es) 2018-10-31
ZA201907091B (en) 2021-05-26
CN113150016A (zh) 2021-07-23
SG11201802961PA (en) 2018-05-30
EA201891057A1 (ru) 2018-12-28
BR122020022280B1 (pt) 2022-05-03
EP3368541B1 (en) 2020-05-27
IL258731A (en) 2018-06-28
PH12018500899B1 (en) 2023-02-08
US10065974B2 (en) 2018-09-04
SG10201911406TA (en) 2020-01-30
EP4011887B1 (en) 2024-07-31
MA43131B1 (fr) 2020-07-29
EP3693375A1 (en) 2020-08-12
TWI775556B (zh) 2022-08-21
BR112018008746B1 (pt) 2021-11-16
PH12022551082A1 (en) 2023-03-13
JP2022071010A (ja) 2022-05-13
TWI710565B (zh) 2020-11-21
RS60695B1 (sr) 2020-09-30
US10851118B2 (en) 2020-12-01
AU2020286278B2 (en) 2022-03-17
JP2021075543A (ja) 2021-05-20
US20180346489A1 (en) 2018-12-06
HUE054972T2 (hu) 2021-10-28
IL281503B (en) 2022-01-01
HRP20201046T1 (hr) 2020-10-16
CA3003271A1 (en) 2017-05-04
SG10201911402YA (en) 2020-02-27
WO2017075363A1 (en) 2017-05-04
JP2018533582A (ja) 2018-11-15

Similar Documents

Publication Publication Date Title
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CO2020014009A2 (es) Inhibidores de mcl-1
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CR20150316A (es) Compuestos y sus métodos de empleo
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2021009673A (es) Moduladores de ror-gamma.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MX375706B (es) Compuestos de inhibidor de autotaxina.
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).